ATE291013T1 - Durch einen omega-thiarest substituierte phenyl- prostaglandin-e-derivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven inhaltsstoff enthalten - Google Patents

Durch einen omega-thiarest substituierte phenyl- prostaglandin-e-derivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven inhaltsstoff enthalten

Info

Publication number
ATE291013T1
ATE291013T1 AT99929831T AT99929831T ATE291013T1 AT E291013 T1 ATE291013 T1 AT E291013T1 AT 99929831 T AT99929831 T AT 99929831T AT 99929831 T AT99929831 T AT 99929831T AT E291013 T1 ATE291013 T1 AT E291013T1
Authority
AT
Austria
Prior art keywords
prostaglandin
omega
disease
syndrome
expected
Prior art date
Application number
AT99929831T
Other languages
English (en)
Inventor
Toru Maruyama
Shuichi Ohuchida
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of ATE291013T1 publication Critical patent/ATE291013T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT99929831T 1998-07-15 1999-07-14 Durch einen omega-thiarest substituierte phenyl- prostaglandin-e-derivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven inhaltsstoff enthalten ATE291013T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20075298 1998-07-15
PCT/JP1999/003798 WO2000003980A1 (fr) 1998-07-15 1999-07-14 DERIVES DE PHENYL-POSTAGLANDINE E 5-THIA-φ-SUBSTITUES, PROCEDE DE PRODUCTION DESDITS DERIVES ET MEDICAMENTS CONTENANT LESDITS DERIVES EN TANT QUE PRINCIPE ACTIF

Publications (1)

Publication Number Publication Date
ATE291013T1 true ATE291013T1 (de) 2005-04-15

Family

ID=16429595

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99929831T ATE291013T1 (de) 1998-07-15 1999-07-14 Durch einen omega-thiarest substituierte phenyl- prostaglandin-e-derivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven inhaltsstoff enthalten

Country Status (21)

Country Link
US (1) US6462081B1 (de)
EP (1) EP1097922B1 (de)
JP (1) JP3174563B2 (de)
KR (1) KR100598660B1 (de)
CN (1) CN1173945C (de)
AT (1) ATE291013T1 (de)
AU (1) AU763668B2 (de)
BR (1) BR9912813B1 (de)
CA (1) CA2336952C (de)
DE (1) DE69924258T2 (de)
DK (1) DK1097922T3 (de)
ES (1) ES2239448T3 (de)
HU (1) HUP0204170A3 (de)
NO (1) NO327781B1 (de)
NZ (1) NZ509293A (de)
PT (1) PT1097922E (de)
RU (1) RU2220135C2 (de)
TR (1) TR200100623T2 (de)
TW (1) TWI249520B (de)
WO (1) WO2000003980A1 (de)
ZA (1) ZA200100295B (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2364948C (en) 1999-03-05 2011-04-26 Duke University C16 unsaturated fp-selective prostaglandins analogs
CA2303060A1 (en) * 1999-04-14 2000-10-14 United States Gear Corporation Towed vehicle brake controller
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
EP1226825A4 (de) * 1999-10-07 2004-08-11 Ono Pharmaceutical Co Heilmittel für die erektile dysfunktion
BR0015781A (pt) * 1999-11-24 2002-12-31 Ono Pharmaceutical Co Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
TWI247606B (en) * 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
KR20020067594A (ko) * 2000-01-05 2002-08-22 오노 야꾸힝 고교 가부시키가이샤 5-티아-ω-치환 페닐-프로스타글란딘 Ｅ-알콜, 이들의제조 방법 및 이들을 유효 성분으로서 함유하는 약제
PT1132086E (pt) * 2000-01-31 2006-09-29 Pfizer Prod Inc Utilizacao de agonistas selectivos para o receptor da prostaglandina (pge2) 4 (ep4) para o tratamento de falha renal aguda e cronica
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US6586462B2 (en) * 2000-10-20 2003-07-01 Allergan, Inc. ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
GB0030541D0 (en) * 2000-12-14 2001-01-31 Glaxo Group Ltd Medical uses
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
EP1408961B1 (de) * 2001-07-16 2007-07-11 F. Hoffmann-La Roche Ag 2 pyrrolidon-derivate als prostanoid-agonisten
CN101921220B (zh) * 2001-07-23 2013-05-22 小野药品工业株式会社 治疗与骨质损失有关的疾病的含有ep4激动剂作为活性成分的药物组合物
CN1893977B (zh) * 2001-07-23 2012-12-05 小野药品工业株式会社 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物
NZ531153A (en) * 2001-08-09 2005-10-28 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
JP2003078830A (ja) * 2001-09-03 2003-03-14 Sony Corp デジタル放送受信装置および通信情報伝送方法
EP1467738A1 (de) * 2001-10-08 2004-10-20 Medical Research Council Verwendung von prostaglandin e synthase inhibitoren, oder ep2/ep4 rezeptor antagonisten, zur behandlung von uterine krankheiten
DE60222168T2 (de) * 2001-10-31 2008-05-15 Medical Research Council Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
WO2003037373A1 (en) * 2001-10-31 2003-05-08 Medical Research Council Use of an ep2 or ep4 receptor antagonist and/or a cox-1 inhibitor for treating cervical cancer
WO2003041717A1 (fr) * 2001-11-12 2003-05-22 Ono Pharmaceutical Co., Ltd. Preparation pelliculaire persistante pour administration localisee contenant un derive de prostaglandine
AU2003209571A1 (en) * 2002-03-18 2003-09-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
GB0208785D0 (en) * 2002-04-17 2002-05-29 Medical Res Council Treatment methtods
US20050239872A1 (en) * 2002-06-06 2005-10-27 Xavier Billot 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
US7737182B2 (en) 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
CA2465103C (en) * 2002-08-09 2011-04-26 Taisho Pharmaceutical Co., Ltd. Use of a prostaglandin derivative as an anti-pruritic agent
EP1563846B1 (de) 2002-10-10 2012-08-29 Ono Pharmaceutical Co., Ltd. Endogene reparaturfaktoren herstellende promoter
JP4477504B2 (ja) * 2002-11-13 2010-06-09 大正製薬株式会社 鎮痒剤
NZ541603A (en) * 2003-02-07 2008-03-28 Ono Pharmaceutical Co Carbonyl phenyl propanoic acid derivative compounds
US7855226B2 (en) * 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
CA2513652A1 (en) 2003-03-03 2004-09-16 Applied Research Systems Ars Holding N.V. G-lactam derivatives as prostaglandin agonists
WO2005012232A2 (en) 2003-07-18 2005-02-10 Applied Research Systems Ars Holding N.V. Hydrazide derivatives as prostaglandin receptors modulators
CN1946391A (zh) * 2004-04-20 2007-04-11 辉瑞产品公司 包含α－2－δ配体的组合
EP1782830A4 (de) * 2004-08-10 2009-07-29 Ono Pharmaceutical Co Mittel zur prävention und/oder behandlung von erkrankungen der unteren harnwege mit ep4 agonist
WO2006016695A1 (ja) * 2004-08-10 2006-02-16 Ono Pharmaceutical Co., Ltd. Ｅｐ４アゴニストを含有してなる高カリウム血症の予防および／または治療剤
JP2008518013A (ja) * 2004-10-26 2008-05-29 アラーガン、インコーポレイテッド プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法
JPWO2006075690A1 (ja) * 2005-01-14 2008-06-12 小野薬品工業株式会社 安定な医薬組成物
KR20080000647A (ko) 2005-04-28 2008-01-02 오노 야꾸힝 고교 가부시키가이샤 경피 흡수 제제
GB0524103D0 (en) 2005-11-26 2006-01-04 Medical Res Council Healing
US7511168B2 (en) * 2006-01-18 2009-03-31 Shih-Yi Wei Processes and intermediates for the preparations of prostaglandins
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
JP5262720B2 (ja) 2006-10-26 2013-08-14 小野薬品工業株式会社 貼付剤
NZ577109A (en) 2006-12-15 2011-12-22 Glaxo Group Ltd Benzamide derivatives as ep4 receptor agonists
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
AU2008246579A1 (en) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
JP2012507552A (ja) 2008-10-29 2012-03-29 アエリエ・ファーマシューティカルズ・インコーポレーテッド プロスタグラジンのアミノ酸塩
KR101172638B1 (ko) 2008-12-30 2012-08-08 조선대학교산학협력단 신규한 티아졸리딘디온 유도체 및 그의 용도
EP3828172A1 (de) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Hemmer mit doppelmechanismus zur behandlung von erkrankungen
PH12013500205A1 (en) * 2010-07-30 2017-08-23 Allergan Inc Compounds and methods for skin repair
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
WO2012112757A2 (en) 2011-02-17 2012-08-23 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2678022A2 (de) 2011-02-23 2014-01-01 Allergan, Inc. Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe
WO2013123272A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123270A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814527A1 (de) 2012-02-16 2014-12-24 Allergan, Inc. Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe
EP2814526B1 (de) 2012-02-16 2016-11-02 Allergan, Inc. Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe
EP2846793A1 (de) 2012-05-09 2015-03-18 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur vorbeugung oder behandlung von chronisch obstruktiver lungenerkrankung
HUE031885T2 (en) 2012-07-19 2017-08-28 Cayman Chemical Co Inc Difluoro lactam preparations for EP4-mediated osteo-related diseases and conditions
ES2733998T3 (es) 2012-10-29 2019-12-03 Cardio Incorporated Agente terapéutico específico de enfermedad pulmonar
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
US20140275160A1 (en) 2013-03-15 2014-09-18 Aerie Pharmaceuticals, Inc. Combination therapy
KR20160048054A (ko) 2013-07-19 2016-05-03 카이맨 케미칼 컴파니 인코포레이티드 골 성장의 촉진을 위한 방법, 시스템 및 조성물
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
CN109640966A (zh) 2016-08-31 2019-04-16 爱瑞制药公司 眼用组合物
WO2018183911A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58198466A (ja) 1982-05-12 1983-11-18 Teijin Ltd ５−チアプロスタグランジン類およびその製造法
JPH072711B2 (ja) * 1986-09-24 1995-01-18 帝人株式会社 プロスタグランジンｅ▲下１▼誘導体の製造法
EP0386901A1 (de) * 1989-02-20 1990-09-12 Ono Pharmaceutical Co., Ltd. 5-Hetero-6-oxo-PGE-Derivate
JPH03223244A (ja) * 1989-02-20 1991-10-02 Ono Pharmaceut Co Ltd ５―ヘテロ―６―オキソ―ｐｇｅ誘導体、それらの製造方法およびそれらを含有する薬剤
JP3579448B2 (ja) * 1993-12-29 2004-10-20 大正製薬株式会社 プロスタグランジン誘導体、その塩およびその使用

Also Published As

Publication number Publication date
JP3174563B2 (ja) 2001-06-11
NO327781B1 (no) 2009-09-21
BR9912813A (pt) 2001-05-02
CN1312796A (zh) 2001-09-12
US6462081B1 (en) 2002-10-08
EP1097922A4 (de) 2003-02-12
TR200100623T2 (tr) 2001-06-21
CN1173945C (zh) 2004-11-03
RU2220135C2 (ru) 2003-12-27
KR100598660B1 (ko) 2006-07-13
CA2336952C (en) 2009-09-15
TWI249520B (en) 2006-02-21
WO2000003980A1 (fr) 2000-01-27
EP1097922B1 (de) 2005-03-16
ZA200100295B (en) 2002-07-10
AU4651899A (en) 2000-02-07
DK1097922T3 (da) 2005-05-30
KR20010053386A (ko) 2001-06-25
DE69924258D1 (de) 2005-04-21
NO20010213L (no) 2001-03-15
NO20010213D0 (no) 2001-01-12
CA2336952A1 (en) 2000-01-27
NZ509293A (en) 2003-05-30
BR9912813B1 (pt) 2010-11-30
DE69924258T2 (de) 2006-01-26
ES2239448T3 (es) 2005-09-16
HUP0204170A2 (hu) 2003-04-28
EP1097922A1 (de) 2001-05-09
HUP0204170A3 (en) 2005-03-29
AU763668B2 (en) 2003-07-31
PT1097922E (pt) 2005-06-30

Similar Documents

Publication Publication Date Title
DE69924258D1 (de) Durch einen omega-thiarest substituierte phenyl-prostaglandin-e-derivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven inhaltsstoff enthalten
NL300006I2 (nl) Imidazolylalkeenzuurderivaten.
KR970704435A (ko) 헤테로시클릭 화합물의 도파민-D 리간드로서의 용도(Use of Heterocyclic Compounds as Dopamines-D Ligands)
DE69818286D1 (de) Pyridylverbindungen und diese enthaltende pharmazeutische zubereitungen
EP2266569A3 (de) Heterozyklische Derivate und ihre Verwendung als Stearoyl-Coa-Desaturase-Inhibitoren
YU70901A (sh) Derivati 1,4-benzotiazepin-1,1 dioksida zamenjeni radikalima šećera, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena
RU2004126950A (ru) Использование выделяющих co соединений при изготовлении лекарственного средства для лечения воспалительных заболеваний
EP2269610A3 (de) Heterozyklische Derivate und ihre Verwendung als Stearoyl-Coa-Desaturase-Inhibitoren
CA2217455A1 (fr) Nouveaux derives substitues, de biphenyle ou de phenylpiridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TR200402656T4 (tr) Antikanser ajanları olarak faydalı tiyofen türevleri
DE59208974D1 (de) Neue pyrazinderivative, ihre herstellung und verwendung
DE60220255T2 (de) N-phenylarylsulfonamidverbindung, arzneimittel, das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung
JPS6217994B2 (de)
RU94038256A (ru) Производные пиразолопиримидина, способ их получения, фармацевтические композиции на их основе
IT1271007B (it) Derivati del 2-ammino-1,2,3,4-tetraidronaftalene attivi sul sistema cardiovascolare
EP1258473A4 (de) Benzoesäurederivate, verfahren zu ihrer herstellung und medikamente, die diese als aktiven wirkstoff enthalten
IT1265077B1 (it) Derivati del cicloeptimmidazolo, metodo per la loro produzione e agenti terapeutici contenenti questi composti
ES2247060T3 (es) Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimericas en asociacion con un agente antihipertensor para una utilizacion terapeutica en el tratamiento de la hipertension arterial.
ATE269352T1 (de) 4-benzylaminochinoline konjugate mit gallensaeure und ihre heteroanalogen, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und deren anwendung
ITMI931723A1 (it) Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari
ATE151770T1 (de) Cephalosporinverbindungen und deren herstellung
KR890009890A (ko) 하이드록시 피리미딘의 아실 유도체
ATE386735T1 (de) Substituierte benzoylureidopyridyl-piperidin- und pyrrolidin-carbons urederivate, verfahren zu deren herstellung und deren v erwendung
NO20060739L (no) Hydrazidderivater som prostaglandinreseptor- modulatorer
KR910002818A (ko) 4,5,6,7-사치환된 벤즈옥사졸론

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1097922

Country of ref document: EP